ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Caffeine and preterm infants: multiorgan effects and therapeutic creep: scope to optimise dose and timing.

カフェインと早産児:多臓器への影響と治療の逸脱:投与量とタイミングの最適化の可能性 (機械翻訳の邦題)

Pediatric research2026O'Shea M, Butler L, Holohan S, et al.
研究デザインレビュー
対象ヒト

記録の確認項目

研究デザイン
レビュー
対象
ヒト
出版年
2026
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/03
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

カフェインは早産児の無呼吸治療に約50年使用されてきた。標準用量(負荷量20mg/kg、維持量5-10mg/kg/日)で有効であり、長期的な神経学的利益や他の臓器への改善、免疫調節効果が認められる。しかし、無作為化比較試験の基準と異なる治療の逸脱が指摘され、コクランレビューでは予防的使用のエビデンスは不十分とされる。高用量(80mg/kg)では神経学的異常の増加が報告され、国際的なガイドラインは投与量、タイミング、期間に関してばらつきがある。至適用量や適応を明確化するための大規模試験が求められる。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Caffeine is a methylxanthine used for nearly 50 years in the treatment of apnoea of prematurity (AOP). Caffeine citrate is effective in the treatment of AOP using standard dosing (loading dose 20 mg/kg, maintenance 5-10 mg/kg/day) and is associated with long-term neurological benefits and other improved organ outcomes as well as immunomodulatory effects. Therapeutic creep has been noted in the use of caffeine in preterm infants differing from the criteria in randomised controlled trials. A Cochrane review showed insufficient evidence to support prophylactic use of caffeine citrate in preterm neonates to prevent AOP, although it is still recommended in many national and local guidelines. Concerns about adverse reactions exist with high-dose caffeine regimens with one high-dose trial reporting statistically significant increases in abnormal neurological outcomes compared with standard doses (80 mg/kg compared to 20 mg/kg). International clinical guidelines vary from clinical trials regarding timing, dose, and duration of caffeine therapy. Further clinical research could help to understand optimal doses for different indications, such as peri-extubation, early postnatal use while ventilated, multiorgan and psychoactive effects, and long-term neurodevelopmental outcomes. This review describes the mechanism and multiorgan effects of caffeine highlighting areas of therapeutic creep and uncertainty requiring further research, such as comparative effectiveness trials. IMPACT: Caffeine citrate is indicated for the management of apnoea of prematurity. Therapeutic creep is evident in international guidelines for the use of caffeine citrate in preterm infants. Caffeine has multiorgan effects involving renal, respiratory, and inflammatory responses, which, by optimising dosing and timing, may improve outcomes. Optimising indications, dose, and timing of caffeine citrate in preterm infants in further large-scale trials is warranted and may have other multiorgan benefits.

MeSH

ApneaCaffeineCitratesHumansInfant, NewbornInfant, Premature

DOI 10.1038/s41390-025-04066-1

PMID 40542101

原文・出典を見る →